다우존스 지수

무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.

등록

홈
인베스팅
주식
미국
NASDAQ
Syndax Pharmaceuticals Inc (SNDX)
Syndax Pharmaceuticals Inc (SNDX) 뉴스

SNDX

Syndax Pharmaceuticals (SNDX)

Syndax Pharmaceuticals Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:SNDX

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2025/01/16	07:34	PR Newswire (US)	Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2025/01/13	21:00	PR Newswire (US)	Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2025/01/08	11:20	PR Newswire (US)	Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2025/01/07	21:00	PR Newswire (US)	Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2025/01/04	06:05	PR Newswire (US)	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/12/21	07:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/12/09	21:30	PR Newswire (US)	Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/12/08	08:15	PR Newswire (US)	Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/12/07	06:28	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/12/04	06:05	PR Newswire (US)	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/11/27	21:00	PR Newswire (US)	Syndax Announces Participation at the Citi 2024 Global Healthcare Conference	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/11/16	07:29	PR Newswire (US)	Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/11/12	21:05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/11/12	21:00	PR Newswire (US)	Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/11/06	06:03	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/11/06	06:02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/11/06	06:01	PR Newswire (US)	Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/11/05	23:01	PR Newswire (US)	Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/11/05	23:00	PR Newswire (US)	Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/11/05	23:00	PR Newswire (US)	Syndax Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/11/05	06:01	PR Newswire (US)	Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/11/02	05:05	PR Newswire (US)	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/11/01	20:00	PR Newswire (US)	Syndax Announces Participation in November Investor Conferences	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/10/29	20:00	PR Newswire (US)	Syndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/10/22	05:11	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/10/05	05:05	PR Newswire (US)	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/09/19	06:15	PR Newswire (US)	Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/09/07	05:05	PR Newswire (US)	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/08/16	05:15	Business Wire	Incyte und Syndax melden FDA-Zulassung von Niktimvo™ (Axatilimab-csfr) zur Behandlung der chronischen Graft-versus-Host-Krankheit (GvHD)	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/08/15	19:26	Business Wire	Incyte et Syndax annoncent l’approbation par la FDA américaine de Niktimvo™ (axatilimab-csfr) pour le traitement de la maladie chronique du greffon contre l’hôte (GVHD)	NASDAQ:SNDX	Syndax Pharmaceuticals Inc

검색 관련기사 보기:NASDAQ:SNDX

1 2 3 4 5 6 7 8 9 10 다음 >>

Gold vs US Dollar

Deutsche Telekom (QX)

American Express

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관